INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 175 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2014. The put-call ratio across all filers is 1.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,710,890 | +18.7% | 92,281 | -14.0% | 0.01% | +44.4% |
| Q1 2023 | $1,441,630 | -48.4% | 107,344 | -52.5% | 0.01% | -43.8% |
| Q4 2022 | $2,793,777 | -40.1% | 225,851 | -32.4% | 0.02% | -38.5% |
| Q3 2022 | $4,662,000 | +363.9% | 334,168 | +359.3% | 0.03% | +333.3% |
| Q2 2022 | $1,005,000 | -69.6% | 72,756 | -64.2% | 0.01% | -78.6% |
| Q1 2022 | $3,307,000 | +78.1% | 203,251 | +78.3% | 0.03% | +55.6% |
| Q4 2021 | $1,857,000 | +31.3% | 114,004 | +19.7% | 0.02% | 0.0% |
| Q3 2021 | $1,414,000 | -14.3% | 95,224 | +15.3% | 0.02% | -5.3% |
| Q2 2021 | $1,649,000 | -39.8% | 82,593 | -30.4% | 0.02% | -45.7% |
| Q1 2021 | $2,740,000 | -24.1% | 118,707 | -18.8% | 0.04% | -30.0% |
| Q4 2020 | $3,610,000 | +131.9% | 146,155 | +289.2% | 0.05% | +117.4% |
| Q3 2020 | $1,557,000 | +162.6% | 37,555 | +203.3% | 0.02% | +130.0% |
| Q2 2020 | $593,000 | -71.5% | 12,382 | -62.6% | 0.01% | -82.1% |
| Q1 2020 | $2,082,000 | -71.0% | 33,069 | -42.9% | 0.06% | -57.3% |
| Q4 2019 | $7,176,000 | +305.9% | 57,911 | +117.3% | 0.13% | +274.3% |
| Q3 2019 | $1,768,000 | +137.0% | 26,645 | +184.1% | 0.04% | +150.0% |
| Q2 2019 | $746,000 | +1392.0% | 9,380 | +1776.0% | 0.01% | +600.0% |
| Q4 2018 | $50,000 | +177.8% | 500 | +74.8% | 0.00% | +100.0% |
| Q1 2018 | $18,000 | -91.7% | 286 | -92.3% | 0.00% | -90.9% |
| Q4 2017 | $216,000 | -44.6% | 3,700 | -44.9% | 0.01% | -50.0% |
| Q3 2017 | $390,000 | -19.1% | 6,717 | +68.6% | 0.02% | -29.0% |
| Q2 2017 | $482,000 | +510.1% | 3,983 | +469.0% | 0.03% | +416.7% |
| Q1 2017 | $79,000 | -80.1% | 700 | -80.8% | 0.01% | -81.2% |
| Q4 2016 | $397,000 | +2546.7% | 3,652 | +3021.4% | 0.03% | +3100.0% |
| Q1 2016 | $15,000 | -98.2% | 117 | -97.9% | 0.00% | -97.9% |
| Q4 2015 | $824,000 | +95.7% | 5,515 | +269.4% | 0.05% | +128.6% |
| Q1 2015 | $421,000 | +1258.1% | 1,493 | +646.5% | 0.02% | +950.0% |
| Q4 2014 | $31,000 | -98.7% | 200 | -98.0% | 0.00% | -98.6% |
| Q3 2014 | $2,391,000 | -23.5% | 10,100 | -23.5% | 0.15% | -22.3% |
| Q2 2014 | $3,126,000 | – | 13,209 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $39,083,000 | 9.04% |
| Senvest Management, LLC | 1,152,032 | $70,873,000 | 5.40% |
| Melqart Asset Management (UK) Ltd | 298,200 | $18,345,000 | 2.20% |
| Elk Creek Partners, LLC | 348,454 | $21,437,000 | 1.25% |
| ALTRINSIC GLOBAL ADVISORS LLC | 375,223 | $23,084,000 | 0.93% |
| BB BIOTECH AG | 545,719 | $33,573,000 | 0.93% |
| Virtus ETF Advisers LLC | 14,681 | $903,000 | 0.78% |
| Opus Point Partners Management, LLC | 4,496 | $277,000 | 0.54% |
| Spark Investment Management LLC | 136,500 | $8,397,000 | 0.54% |
| Regal Investment Advisors LLC | 29,511 | $1,816,000 | 0.40% |